GlassScriptPhysician profile
Lipishree Nayak
NPI 1972675742
$2,013.20
in general payments reported to CMS, 2019-2025
16 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.13 · 2020: $51.23 · 2021: $390 · 2022: $438 · 2023: $374 · 2024: $366 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $926.87 | 2020-2025 | Rybelsus, Wegovy |
| Pfizer INC. | $249.18 | 2019-2025 | |
| Exact Sciences Corporation | $198.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $140.87 | 2019-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $128.64 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $96.12 | 2020-2025 | Airsupra |
| Dexcom, INC. | $40.76 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $39.37 | 2022 | |
| Amgen INC. | $34.50 | 2025 | Repatha, Repatha |
| Boston Scientific Corporation | $28.94 | 2025 | Bodyguardian |
| Shield Therapeutics INC | $28.26 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $23.04 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.87 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $20.14 | 2023 | Delstrigo, Pifeltro |
| Glaxosmithkline, LLC. | $20.06 | 2023 | Shingrix |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $16.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lipishree Nayak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.